Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL XR 10 vs BAFIERTAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall XR 10 contains a mixture of amphetamine salts, which are central nervous system stimulants. The dextroamphetamine and levoamphetamine components increase synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals. This action leads to enhanced neurotransmission in the prefrontal cortex and other brain regions involved in attention and executive function.
BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy (off-label)
FDA-approved: Treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.,Off-label: None widely documented.
10 mg orally once daily in the morning; maximum dose 40 mg/day.
120 mg orally once daily.
Dexamphetamine: 10-13 hours in adults (children: 6-8 hours); levoamphetamine: 13-16 hours; clinically, steady-state achieved in approximately 3 days, with twice-daily dosing maintaining therapeutic levels
Approximately 12 hours (range 8–15 hours); permits twice-daily dosing in multiple sclerosis.
Amphetamine is primarily metabolized by hepatic CYP2D6 to 4-hydroxyamphetamine, which is further conjugated. Minor pathways include N-dealkylation and deamination. The drug has a half-life of approximately 10-13 hours.
BAFIERTAM is a prodrug that is rapidly metabolized by esterases in the gastrointestinal tract, blood, and tissues to monomethyl fumarate. Monomethyl fumarate is further metabolized via the tricarboxylic acid (TCA) cycle, with no significant involvement of cytochrome P450 enzymes.
Renal (approximately 30-40% as unchanged amphetamine, remainder as metabolites, including deaminated and oxidized products; urinary p H-dependent elimination: acidic p H increases renal clearance, alkaline p H decreases renal clearance; negligible biliary/fecal elimination)
Primarily via renal excretion as unchanged drug (approximately 80% of the dose); minimal biliary/fecal elimination (<5%).
15-40% bound to plasma proteins, primarily albumin; lower binding in patients with hepatic impairment
30–40% bound to plasma proteins, primarily albumin.
3.0-4.5 L/kg for total amphetamine; high tissue distribution (brain, lungs, kidneys); enters CNS via passive diffusion and active transport
Approximately 0.5–0.7 L/kg; indicates distribution into total body water with limited tissue binding.
Oral: quantitative absorption with 90-100% bioavailability of the total amphetamine content; food does not affect overall absorption but may delay peak concentrations with high-fat meals
Oral: Approximately 50% (due to first-pass metabolism); administer with food to reduce GI irritation.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: not recommended.
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Use with caution in hepatic impairment; reduce dose to 60 mg once daily in Child-Pugh Class B or C.
Children 6-17 years: starting dose 5 mg once daily; increase by 5 mg weekly based on response; maximum 30 mg/day.
Not established in pediatric patients.
Starting dose 5 mg once daily; increase cautiously with monitoring for hypertension, agitation, and cognitive effects.
No specific dose adjustment; use with caution due to age-related decline in renal function.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall XR, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
No black box warning.
Serious cardiovascular events, including sudden death in patients with pre-existing structural cardiac abnormalities; blood pressure and heart rate increases; psychiatric adverse reactions (e.g., exacerbation of psychosis, mania, aggression); seizures; serotonin syndrome if combined with serotonergic drugs; long-term growth suppression in children; peripheral vasculopathy including Raynaud's phenomenon; potential for abuse and dependence.
Lymphopenia: May cause reduction in lymphocyte counts; monitor complete blood count before and periodically during treatment.,Hypersensitivity reactions: Anaphylaxis and angioedema may occur; discontinue if severe.,Progressive multifocal leukoencephalopathy (PML): Reported in patients with prolonged lymphopenia; consider holding therapy if lymphocyte counts drop below 0.2 x 10^9/L.,Hepatic injury: Elevations of liver enzymes have been reported; monitor in patients with pre-existing liver disease.,Flushing and gastrointestinal events: Common; may be managed by taking with food or using aspirin.
Hypersensitivity to amphetamine or any component of the formulation; patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma; agitated states; history of drug abuse; during or within 14 days following MAOI therapy.
Known hypersensitivity to BAFIERTAM, monomethyl fumarate, or any excipient.,Concomitant use with dimethyl fumarate or other fumaric acid esters.
Take ADDERALL XR with or without food. However, high-fat meals may delay absorption and reduce peak concentrations. Avoid consumption of acidic foods or beverages (e.g., citrus fruits, fruit juices, cola) within 1 hour before or after dosing, as acidity can decrease absorption. Vitamin C (ascorbic acid) and other acidifying agents can reduce efficacy; conversely, alkalizing agents (e.g., antacids, sodium bicarbonate) may potentiate effects.
Administer with food to reduce flushing and gastrointestinal adverse effects. Avoid alcohol consumption during treatment as it may exacerbate flushing. No specific dietary restrictions are required.
Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations (ventricular septal defects) and neural tube defects at high doses. Second trimester: Potential for reduced fetal growth and premature delivery. Third trimester: Risk of neonatal withdrawal syndrome (irritability, dysphoria, tremor, hypertonia) and preterm birth.
BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic potential.
Contraindicated during breastfeeding. Amphetamine is excreted into human milk; M/P ratio approximately 3.5. Infant exposure estimated at 4-8% of maternal weight-adjusted dose. Reported adverse effects in infants include irritability, poor feeding, and sleep disturbances.
No data on presence in human milk. M/P ratio unknown. Risk of infant exposure cannot be excluded. Discontinue breastfeeding or drug, considering importance to mother.
Increased clearance during 2nd and 3rd trimesters (hepatic induction) may require dose escalation. Postpartum, clearance returns to nonpregnant levels, requiring dose reduction to avoid toxicity. Individualize dosing based on clinical response and tolerability.
No dose adjustment data; contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately. Pharmacokinetic changes unknown but drug should not be used.
ADDERALL XR (mixed amphetamine salts extended-release) 10 mg is a CNS stimulant indicated for ADHD. Initiate at 10 mg once daily in the morning; titrate in 5-10 mg increments weekly. Swallow capsules whole, or sprinkle contents on applesauce for patients unable to swallow. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Abuse potential is high; use with caution in patients with history of substance abuse. Contraindicated in glaucoma, hyperthyroidism, agitated states, MAOI use within 14 days, and structural cardiac abnormalities.
BAFIERTAM (monomethyl fumarate) is a prodrug of monomethyl fumarate, indicated for relapsing forms of multiple sclerosis. Administer with food to reduce flushing and gastrointestinal adverse effects. Titrate as per recommended schedule to improve tolerability. Monitor complete blood count, liver function tests, and renal function at baseline and periodically. Flushing may be reduced by taking with food or using non-enteric coated aspirin (325 mg) 30 minutes prior. Avoid concurrent use with dimethyl fumarate or other fumaric acid esters.
Take exactly as prescribed once daily in the morning with or without food.,Do not chew or crush the capsule; you may open it and sprinkle the beads on a spoonful of applesauce, then swallow immediately without chewing.,Avoid taking in the afternoon or evening as it may cause difficulty sleeping.,Do not stop abruptly without consulting your doctor; sudden discontinuation may cause withdrawal symptoms.,Report any chest pain, palpitations, shortness of breath, or fainting to your doctor.,This medication has a high potential for abuse; keep in a safe place and do not share with others.,Avoid alcohol and illicit drugs while taking this medication.,Notify your doctor if you have a history of drug dependence, anxiety, bipolar disorder, or seizures.,For patients with ADHD, it may improve focus, attention, and impulse control.,Store at room temperature away from moisture and heat.
Take BAFIERTAM exactly as prescribed, usually twice daily with food.,Flushing and gastrointestinal upset are common but may decrease over time; taking with food and gradual dose titration helps.,Do not crush, chew, or open capsules; swallow whole.,Report any signs of infection, unusual bruising or bleeding, or severe abdominal pain to your healthcare provider.,Avoid consuming alcohol, as it may increase flushing risk.,If you miss a dose, take it as soon as you remember unless it is near the time of the next dose; do not double up.,Inform all healthcare providers that you are taking BAFIERTAM.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL XR 10 vs BAFIERTAM, answered by our medical review team.
ADDERALL XR 10 is a CNS Stimulant that works by Adderall XR 10 contains a mixture of amphetamine salts, which are central nervous system stimulants. The dextroamphetamine and levoamphetamine components increase synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals. This action leads to enhanced neurotransmission in the prefrontal cortex and other brain regions involved in attention and executive function.. BAFIERTAM is a Iron Chelating Agent that works by BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL XR 10 and BAFIERTAM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL XR 10 is: 10 mg orally once daily in the morning; maximum dose 40 mg/day.. The standard adult dose of BAFIERTAM is: 120 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL XR 10 and BAFIERTAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL XR 10 is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations (ventricular septal defects) and neural tube defects a. BAFIERTAM is classified as Category C. BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.